(P051) Intraductal Papillary Neoplasm of the Bile Duct: Prognostic Factors in SEER Outcomes of Benign and Malignant Cases

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Both benign and malignant cases had outcomes dependent upon the location and extent of surgical resection. In malignant cases that are not amenable to surgery, radiation offers a survival benefit. Given the cohort in this analysis, selection bias likely plays a significant role. Further study is required to define the optimal management of IPNB.

Sean Szeja, MD, Todd Swanson, MD, PhD; UT Medical Branch

INTRODUCTION: Intraductal papillary neoplasm of the bile duct (IPNB) may be invasive or noninvasive. Given its rarity, there are limited data on the management and clinical outcomes. The purpose of this study is to use the Surveillance, Epidemiology, and End Results (SEER) database to evaluate prognostic factors: stage, anatomical location, extent of surgery, and the use of radiation therapy (RT).

METHODS: Cases diagnosed from 1978–2011 were downloaded from the SEER database. Inclusion criteria were first primary, known status of surgery, and RT history. Analysis of malignant diagnoses from 2004–2011 incorporated TNM staging. Kaplan-Meier curves calculated overall survival (OS) and disease-specific survival (DSS) in months. Log-rank tests were performed to compare survival.

RESULTS: There were 31 benign cases, with an OS of 92 months; surgery was used in 26 cases, definitive RT was used in 1 case, and adjuvant RT was used in another. Ampulla of Vater (AoV) and other extrahepatic ductal (EHD) locations had statistically similar OS (120 vs 79 mo, respectively; P = .93). For EHD, trends suggested that subtotal resection had the best OS (P = .157), and for AoV locations, radical resection trended toward worse OS (P = .128), with statistical power limited by having eight patients with defined surgical extent at each location. There were 1,309 malignant cases; 542 of these patients did not have surgery, and of this group 77 received RT alone that extended median OS from 3 to 7 months (P = .026) and DSS from 4 to 8 months (P = .074). There were 323 malignant cases diagnosed from 2004–2011: 54% with N0M0 and 20% being T1N0M0. Analysis of all stages combined by location showed, in decreasing order, significantly different median survival times (P < .01): AoV: OS 48 mo, DSS 57 mo; EHD: OS 12 mo, DSS 15 mo; and intrahepatic ductal (IHD): OS 5 mo, DSS 5 mo. Analysis by treatment modality showed that, with regard to OS and DSS, surgery alone was better than surgery and radiation (P < .01), which was better than radiation alone (P < .01), which was similar to results with no treatment. Analysis of T1N0M0 cases showed that smaller extent of resection of primary location correlated with better OS and DSS (P < .05, P < .02, respectively) at EHD but not AoV locations.

CONCLUSIONS: Both benign and malignant cases had outcomes dependent upon the location and extent of surgical resection. In malignant cases that are not amenable to surgery, radiation offers a survival benefit. Given the cohort in this analysis, selection bias likely plays a significant role. Further study is required to define the optimal management of IPNB.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content